BUZZ-BioXcel 在阿尔茨海默氏症相关药物申请获得 FDA 积极反馈后大涨

路透中文

Aug 18

8月18日 - ** 生物制药公司BioXcel Therapeutics BTAI.O股价盘前上涨26.5%至6.93美元

** 该公司称其收到了FDA对BXCL501计划申请的积极反馈 (link)，BXCL501是一种治疗阿尔茨海默病患者躁动的药物。

* * BXCL501目前已获准在医疗监督下使用，该公司正在争取美国食品药品管理局批准在家中使用该药治疗与双相情感障碍或精神分裂症相关的躁动症。

** 公司计划于 2026 年第一季度提交上市申请

** 股价今年累计下跌 8.4

(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2560885621"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2560885621\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2560885621?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-08-18 21:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2560885621","market":"us","top_or_hot":-1,"title":"BUZZ-BioXcel 在阿尔茨海默氏症相关药物申请获得 FDA 积极反馈后大涨","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-BioXcel 在阿尔茨海默氏症相关药物申请获得 FDA 积极反馈后大涨</title></head><body><p>\n<span>8月18日</span><span> - </span>** 生物制药公司BioXcel <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>BTAI.O</span>股价盘前上涨26.5%至6.93美元</p><p>** 该公司称其收到了FDA对BXCL501计划申请的积极反馈 (<span>link</span>)，BXCL501是<span>一种治疗阿尔茨海默病患者躁动的药物</span>。</p><p>*<span> * BXCL501目前已获准在医疗监督下使用，该公司正在争取<a href=\"https://laohu8.com/S/USFD\">美国食品</a>药品管理局批准在家中使用该药 </span>治疗与双相情感障碍或精神分裂症相关的躁动症。</p><p>** 公司计划于 2026 年第一季度提交上市申请</p><p>** 股价今年累计下跌 8.4</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-BioXcel 在阿尔茨海默氏症相关药物申请获得 FDA 积极反馈后大涨</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-BioXcel 在阿尔茨海默氏症相关药物申请获得 FDA 积极反馈后大涨\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2025-08-18 21:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-BioXcel 在阿尔茨海默氏症相关药物申请获得 FDA 积极反馈后大涨</title></head><body><p>\n<span>8月18日</span><span> - </span>** 生物制药公司BioXcel <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>BTAI.O</span>股价盘前上涨26.5%至6.93美元</p><p>** 该公司称其收到了FDA对BXCL501计划申请的积极反馈 (<span>link</span>)，BXCL501是<span>一种治疗阿尔茨海默病患者躁动的药物</span>。</p><p>*<span> * BXCL501目前已获准在医疗监督下使用，该公司正在争取<a href=\"https://laohu8.com/S/USFD\">美国食品</a>药品管理局批准在家中使用该药 </span>治疗与双相情感障碍或精神分裂症相关的躁动症。</p><p>** 公司计划于 2026 年第一季度提交上市申请</p><p>** 股价今年累计下跌 8.4</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250818:nL4S3UA0Q0:1","article_id":"2560885621","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2560885621","pubTimestamp":1755522683,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"** 公司计划于 2026 年第一季度提交上市申请** 股价今年累计下跌 8.4(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","BTAI":"Bioxcel Therapeutics Inc."},"translate_title":"BUZZ-BioXcel surges after receiving positive FDA feedback on Alzheimer's-related drug application","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BTAI":0.9},"content_text":"BUZZ-BioXcel 在阿尔茨海默氏症相关药物申请获得 FDA 积极反馈后大涨\n8月18日 - ** 生物制药公司BioXcel Therapeutics BTAI.O股价盘前上涨26.5%至6.93美元** 该公司称其收到了FDA对BXCL501计划申请的积极反馈 (link)，BXCL501是一种治疗阿尔茨海默病患者躁动的药物。* * BXCL501目前已获准在医疗监督下使用，该公司正在争取美国食品药品管理局批准在家中使用该药 治疗与双相情感障碍或精神分裂症相关的躁动症。** 公司计划于 2026 年第一季度提交上市申请** 股价今年累计下跌 8.4(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}